ArticleJournal of fungi (Basel, Switzerland)2023
Protective Efficacy of Anti-Hyr1p Monoclonal Antibody against Systemic Candidiasis Due to Multi-Drug-Resistant
Article in Journal of fungi (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 30 citations in OpenAlex.
- The urgent and challenging superbug fungus Candidozyma auris (formerly Candida auris): a comprehensive review.Antonie van Leeuwenhoek · 2026Review
- Diabetes and Immunosuppression Drive Distinct Patterns ofbioRxiv : the preprint server for biology · 2026Article
- β-Glucan chitosan particle provides cross-protection against multi-drug-resistant Candida auris.NPJ vaccines · 2026Article
- Protein-related hydrophobicity differences among strains belonging toMicrobiology spectrum · 2026Article
- Visible Photosensitizing Disinfectant Spray for Combating Multidrug-ResistantExploration (Beijing, China) · 2026Article
- Review
- Xenosiderophore transporter gene expression and clade-specific filamentation in Candida auris killifish (Aphanius dispar) infection.Communications biology · 2025Article
- Next-generation Candida albicans vaccine VXV-01 containing recombinant Als3p and Hyr1p antigens for invasive Candida infections.Scientific reports · 2025Article
- Evaluation of the Ca37 Monoclonal Antibody Targeting Alcohol Dehydrogenase AgainstJournal of fungi (Basel, Switzerland) · 2025Article
- β-Glucan Chitosan Particle Provides Cross-Protection Against Multi-Drug- Resistant Candida auris.Research square · 2025Article
- Diagnostic Potential of a Recombinant Candida albicans Hyr1 Protein.Mycopathologia · 2025Article
- Next-generation Candida albicans recombinant Als3p and Hyr1p dual antigen vaccine for invasive Candida infections.Research square · 2025Article
- Monoclonal antibodies targeting Candida disrupt biofilms and inhibit growth across global clinical isolates.iScience · 2025Article
- Innovative antifungal strategies to combat drug-resistantFrontiers in cellular and infection microbiology · 2025Review
- Genomics insights of candidiasis: mechanisms of pathogenicity and drug resistance.Frontiers in microbiology · 2025Review
- The rising challenge ofFrontiers in microbiology · 2025Review
- Adjunctive GM-CSF therapy enhances host defense against systemicFrontiers in immunology · 2025Article
- Vertebrate and invertebrate animal infection models of Candida auris pathogenicity.Current opinion in microbiology · 2024Review
- Innate immune response to Candida auris.Current opinion in microbiology · 2024Review
- Current Perspectives of Antifungal Therapy: A Special Focus onJournal of fungi (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.